INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Inhibrx Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Market Cap | $1.32B | $164.85M |
| Enterprise Value | $1.36B | $87.06M |
Income (trailing twelve months)
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Operating Income | -$127.81M | -$21.44M |
| Pretax Income | -$138.18M | -$14.45M |
| Net Income | -$138.18M | -$22.46M |
| EBITDA | -$125.61M | -$16.91M |
| EPS (Diluted) | -$8.88 | -$0.83 |
Returns
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -1773.6% | -53.1% |
| Return on Assets (ROA) | -75.4% | -41.0% |
| Return on Capital Employed (ROCE) | -101.3% | -37.8% |
Growth
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -16.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -36.8% | 6.42% |
Balance sheet
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $133.34M | $62.42M |
| Total Debt | $176.29M | $120.13M |
| Net Cash (Debt) | -$42.94M | $15.68M |
| Net Cash Per Share | -$2.92 | $0.66 |
| Equity (Book Value) | -$52.98M | $48.79M |
| Book Value Per Share | -$3.60 | $1.36 |
| Tangible Book Value | -$52.98M | $23.06M |
| Working Capital | $114.15M | $75.77M |
Financial position
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Current Ratio | 5.07 | 3.30 |
| Quick Ratio | 4.75 | 2.39 |
| Interest Coverage | -8.21 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$131.89M | -$12.35M |
| Capital Expenditures | -$10.00K | -$1.06M |
| Free Cash Flow | -$131.90M | -$20.28M |
| FCF Per Share | -$8.96 | -$0.42 |
Efficiency
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Profits Per Employee | -$1.26M | -$703.34K |
| Employee Count | 110 | 74 |
Dividends and yields
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -10.5% | -22.7% |
| FCF Yield | -9.98% | -9.07% |
Shares
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 14,717,700 | 58,179,650 |
| Shares Change (YoY) | 0.63% | 11.1% |
| Shares Change (QoQ) | 0.70% | 0.54% |
| Float | 9,514,970 | 49,173,100 |
| Shares Held by Insiders | 35.4% | 11.6% |
| Shares Held by Institutions | 97.4% | 59.4% |
Taxes
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Income Tax | $3.00K | $91.50K |
Scores
| Measure | Inhibrx Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -0.89 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Inhibrx Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.